Banco Bilbao Vizcaya Argentaria S.A. Has $2.63 Million Stake in Incyte Co. (NASDAQ:INCY)

Banco Bilbao Vizcaya Argentaria S.A. lifted its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 409.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,023 shares of the biopharmaceutical company's stock after acquiring an additional 30,565 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Incyte were worth $2,626,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Barclays PLC lifted its stake in shares of Incyte by 8.1% in the third quarter. Barclays PLC now owns 1,031,932 shares of the biopharmaceutical company's stock valued at $68,208,000 after purchasing an additional 77,542 shares during the period. Tri Ri Asset Management Corp purchased a new stake in shares of Incyte in the third quarter valued at $3,292,000. GAMMA Investing LLC boosted its stake in shares of Incyte by 18.3% during the 4th quarter. GAMMA Investing LLC now owns 5,764 shares of the biopharmaceutical company's stock worth $398,000 after purchasing an additional 890 shares during the last quarter. Everence Capital Management Inc. acquired a new position in Incyte in the 4th quarter valued at $265,000. Finally, Nordea Investment Management AB increased its stake in Incyte by 9.2% in the fourth quarter. Nordea Investment Management AB now owns 13,738 shares of the biopharmaceutical company's stock valued at $945,000 after purchasing an additional 1,153 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company's stock.

Analyst Upgrades and Downgrades

INCY has been the subject of a number of research analyst reports. Cantor Fitzgerald restated a "neutral" rating on shares of Incyte in a report on Friday, January 10th. Royal Bank of Canada lifted their price target on shares of Incyte from $64.00 to $67.00 and gave the stock a "sector perform" rating in a research note on Wednesday. JPMorgan Chase & Co. reduced their target price on Incyte from $70.00 to $68.00 and set a "neutral" rating for the company in a research note on Monday, April 21st. StockNews.com raised Incyte from a "buy" rating to a "strong-buy" rating in a report on Wednesday. Finally, Citigroup cut their target price on shares of Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Incyte presently has an average rating of "Hold" and a consensus price target of $73.94.

Incyte Stock Performance

INCY traded down $0.63 during midday trading on Thursday, reaching $62.03. The company's stock had a trading volume of 2,438,897 shares, compared to its average volume of 2,363,580. Incyte Co. has a twelve month low of $51.75 and a twelve month high of $83.95. The stock has a market cap of $12.00 billion, a P/E ratio of 229.75, a PEG ratio of 0.41 and a beta of 0.89. The company has a fifty day simple moving average of $63.01 and a 200 day simple moving average of $68.90. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, beating the consensus estimate of $1.01 by $0.15. Incyte had a net margin of 0.77% and a return on equity of 0.05%. The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $996.17 million. During the same period in the prior year, the company earned $0.64 EPS. The business's quarterly revenue was up 19.5% compared to the same quarter last year. Research analysts expect that Incyte Co. will post 4.86 earnings per share for the current year.

Insider Buying and Selling at Incyte

In other news, EVP Sheila A. Denton sold 599 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total value of $41,924.01. Following the sale, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,809,101.52. The trade was a 2.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the transaction, the executive vice president now directly owns 33,567 shares of the company's stock, valued at $2,272,150.23. This represents a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,475 shares of company stock valued at $2,424,751 in the last quarter. Corporate insiders own 17.60% of the company's stock.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.